Physician profile
Alaa Latif
NPI 1619965506
$3,061.97
in general payments reported to CMS, 2019-2025
29 companies · $16.26 in 2025
The $16.26 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.84 · 2020: $54.37 · 2021: $27.20 · 2022: $706 · 2023: $1,190 · 2024: $1,009 · 2025: $16.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.31 |
| Education | $449.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $514.23 | 2021-2024 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $349.98 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $329.47 | 2019-2024 | Imbruvica, Darzalex, Talvey |
| Incyte Corporation | $260.43 | 2023-2024 | Jakafi |
| Celgene Corporation | $240.75 | 2022-2023 | Pomalyst, Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $120.46 | 2022-2023 | Imbruvica, Epkinly |
| Aveo Pharmaceuticals, INC. | $119.06 | 2022-2024 | Fotivda |
| Amgen INC. | $118.07 | 2022-2023 | Lumakras, Nplate, Xgeva |
| Sobi, INC | $111.50 | 2022-2024 | |
| Beigene USA, INC. | $99.14 | 2022-2024 | Brukinsa |
| Pfizer INC. | $96.13 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $85.75 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $84.93 | 2020-2024 | Enhertu, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $76.39 | 2023-2024 | Ninlaro, Iclusig |
| Emd Serono, INC. | $57.95 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $56.91 | 2022-2024 | Ultomiris |
| Genzyme Corporation | $49.45 | 2022 | |
| Deciphera Pharmaceuticals INC. | $47.95 | 2023-2024 | Qinlock |
| Adc Therapeutics America, INC. | $33.71 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.84 | 2023 | |
| Seagen INC. | $31.26 | 2023 | Padcev |
| Agios Pharmaceuticals, INC. | $25.21 | 2024 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $21.70 | 2024 | |
| Springworks Therapeutics, INC. | $21.26 | 2024 | Ogsiveo |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $16.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.16 | 2022 | |
| Medtronic USA, INC. | $13.56 | 2019 | |
| Genentech USA, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Latif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.